2-methyl-2-(2,2,2-trichloro-ethoxy)-propane | 67967-06-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-2-(2,2,2-trichloro-ethoxy)-propane
• 英文别名: tert.-Butyl-<2,2,2-trichlor-aethyl>-aether；Propane, 2-methyl-2-(2,2,2-trichloroethoxy)-；2-methyl-2-(2,2,2-trichloroethoxy)propane
• CAS: 67967-06-0
• 化学式: C₆H₁₁Cl₃O
• 分子量: 205.512
• InChiKey: GLGXKALTCAZDPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-2-(2,2,2-trichloro-ethoxy)-propane 在 氯化亚砜 作用下， 生成 1,2,2,2-tetrachloroethyl tert-butyl ether
  参考文献：
  名称：

  Polarity, polarizability anisotropy, and conformations of 1,2,2,2-tetrachloroethyl alkyl ethers

  摘要：

  DOI：

  10.1007/bf00956085
• 作为产物：
  描述：

  2,2,2-三氯乙醇 、 异丁烯 在 ion-exchange resin + form> 作用下， 生成 2-methyl-2-(2,2,2-trichloro-ethoxy)-propane
  参考文献：
  名称：

  Pola,J. et al., Collection of Czechoslovak Chemical Communications, 1978, vol. 43, p. 760 - 768

  摘要：

  DOI：

文献信息

• NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US20190023657A1

  公开（公告）日：2019-01-24

  The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

  本发明旨在提供一种具有TrkA抑制作用的化合物，其药学上可接受的盐或其溶剂合物，以及含有其作为活性成分的药物组合物，特别用于TrkA参与的疾病（疼痛、癌症、炎症/炎症性疾病、过敏疾病、皮肤疾病、神经退行性疾病、传染病、干燥综合征、子宫内膜异位症、肾脏疾病、骨质疏松症等）的预防和/或治疗剂。具体地，本发明提供一种化合物或其光学异构体，其药学上可接受的盐、其溶剂合物或类似物，该化合物由式（I）表示：
• NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：EP3617195A1

  公开（公告）日：2020-03-04

  The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

  本发明的目的是提供一种具有TrkA抑制作用的化合物、其药学上可接受的盐或其溶液剂、含有其作为活性成分的药物组合物，以及用于医疗用途的预防和/或治疗剂，特别是用于TrkA参与的疾病（疼痛、癌症、炎症/炎症性疾病、过敏性疾病、皮肤病、神经退行性疾病、传染性疾病、Sjogren综合征、子宫内膜异位症、肾脏疾病、骨质疏松症等）。具体而言，本发明提供了一种由式（I）表示的化合物或其光学异构体、其药学上可接受的盐、其溶液或类似物：
• Tetrahydronaphthyl urea derivative
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US10399945B2

  公开（公告）日：2019-09-03

  The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

  本发明的目的是提供一种具有TrkA抑制作用的化合物、其药学上可接受的盐或其溶液剂、含有其作为活性成分的药物组合物，以及用于医疗用途的预防和/或治疗剂，特别是用于TrkA参与的疾病（疼痛、癌症、炎症/炎症性疾病、过敏性疾病、皮肤病、神经退行性疾病、传染性疾病、Sjogren综合征、子宫内膜异位症、肾脏疾病、骨质疏松症等）。具体而言，本发明提供了一种由式（I）表示的化合物或其光学异构体、其药学上可接受的盐、其溶液或类似物：
• Intermediate compound of novel tetrahydronaphthyl urea derivative
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US10927079B2

  公开（公告）日：2021-02-23

  An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)⋅(D-TA): in which p represents an integer of 0 to 4; R1 each independently represent a halogen atom, a cyano group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a hydroxy C1-6 alkyl group, a cyanated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkyl group, a mono-/di-C2-7 alkanoyl amino group, a carboxamide group, or a C1-6 alkoxy carbonyl group; and R2a and R2b each independently represent a C1-6 alkyl group.

  公开了一种中间体化合物、其药学上可接受的盐或其溶液，其中中间体化合物由式 (AM-2-RR)⋅(D-TA) 表示： 其中 p 代表 0 至 4 的整数；R1 各自独立地代表卤素原子、氰基、C1-6 烷基、卤代 C1-6 烷基、羟基 C1-6 烷基、氰代 C1-6 烷基、卤代 C1-6 烷氧基、C1-6 烷氧基 C1-6 烷基、单-/二-C2-7 烷酰基氨基、羧酰胺基或 C1-6 烷氧基羰基；以及 R2a 和 R2b 各自独立地代表 C1-6 烷基。
• Villieras,J.; Normant,H., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1967, vol. 264, p. 593 - 596
  作者：Villieras,J.、Normant,H.

  DOI：——

  日期：——